Provista Diagnostics has achieved consecutive record weekly COVID PCR testing volumes for the weeks of Dec. 13, 2021 and Dec. 20, 2021.
The COVID PCR testing volumes—which are performed via a highly automated CLIA/CAP PCR and cPass neutralizing antibody COVID-19 testing laboratory—were primarily driven by reference lab business from a New York-based PCR testing lab that could not fulfill the testing demand from its location.
“The demand for PCR testing is rapidly increasing in pockets of the United States, and we expect this to continue beyond the holiday surge as individuals, schools and employers seek to create safe environments, especially in areas with low vaccination rates,” says Gerald E. Commissiong, president & CEO of Todos Medical, the parent company of Provista Diagnostics. “Given the pending ‘vaccine or test’ mandate from the Biden Administration that will impose testing requirements on the 38% of the US adult population that have yet to be fully vaccinated against COVID-19, we see the recent scarcity of testing combined with the pending mandate creating demand for a very significant increase in long-term institutional COVID PCR testing for Provista.”
Recent data emerging from Israel suggests neutralizing antibody titers in response to the Pfizer/BioNTech Comirnaty vaccine begins to wane after 4 months from full-vaccination, and that booster shots of Comirnaty begin to wane after 10 weeks from the booster shot. A fourth shot (the “Second Booster”) was recently authorized in Israel for the immune-compromised and those 60+, and a study is underway to determine the durability of a Second Booster for the general population.
“Further, when you combine these realities with a recent uptick in interest in boosters to buttress vaccine or infection-acquired immunity against Omicron, we are beginning to see a marked increase in interest for the cPass neutralizing antibody test to monitor levels of circulating neutralizing antibody testing and allow patients to make rapid, data-driven decisions to get their booster shots, especially given emerging data that suggests high neutralizing antibody-titers produced from a recent booster shot is the most likely to protect an individual against Omicron infection,” says Commissiong.
For more information on Provista Diagnostics’ CLIA/CAP certified lab please visit www.provistadx.com.